Cancer Research Grants Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murphy, K. M.
Right arrow Articles by Kern, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murphy, K. M.
Right arrow Articles by Kern, S. E.
[Cancer Research 62, 3789-3793, July 1, 2002]
© 2002 American Association for Cancer Research

Molecular Biology and Genetics

Evaluation of Candidate Genes MAP2K4, MADH4, ACVR1B, and BRCA2 in Familial Pancreatic Cancer

Deleterious BRCA2 Mutations in 17%1

Kathleen M. Murphy, Kieran A. Brune, Constance Griffin, Jennifer E. Sollenberger, Gloria M. Petersen, Ravi Bansal, Ralph H. Hruban and Scott E. Kern2

Departments of Pathology [K. M. M., K. A. B., C. G., R. H. H., S. E. K.] and Oncology [C. G., J. E. S., R. H. H., S. E. K.], The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, and The Mayo Clinic, Rochester, Minnesota 55905 [G. M. P.]

It is estimated that familial aggregation and genetic susceptibility play a role in as many as 10% of pancreatic ductal adenocarcinomas. To investigate the role of germ-line mutations in the etiology of pancreatic cancer, we have analyzed samples from patients with pancreatic cancer enrolled in the NFPTR for mutations in four tumor suppressor candidate genes: (a) MAP2K4; (b) MADH4; (c) ACVR1B; and (d) BRCA2 by direct sequencing of constitutional DNA. These genes are mutated in clinically sporadic pancreatic cancer, but germ-line mutations are either not reported or anecdotal in familial pancreatic cancer. Pancreatic cancer patient samples were selected from kindreds in which three or more family members were affected with pancreatic cancer, at least two of which were first-degree relatives. No mutations were identified in mitogen-activated protein kinase kinase 4 (0 of 22), MADH4 (0 of 22), or ACVR1B (0 of 29), making it unlikely that germ-line mutations in these genes account for a significant number of inherited pancreatic cancers. BRCA2 gene sequencing identified five mutations (5 of 29, 17.2%) that are believed to be deleterious and one point mutation (M192T) unreported previously. Three patients harbored the common 6174delT frameshift mutation, one had the splice site mutation IVS 16–2A > G, and one had the splice site mutation IVS 15–1G > A. Two of the five BRCA2 mutation carriers reported a family history of breast cancer, and none reported a family history of ovarian cancer. These findings confirm the increased risk of pancreatic cancer in individuals with BRCA2 mutations and identify germ-line BRCA2 mutations as the most common inherited genetic alteration yet identified in familial pancreatic cancer.




This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. P. Klein, M. Borges, M. Griffith, K. Brune, S.-M. Hong, N. Omura, R. H. Hruban, and M. Goggins
Absence of Deleterious Palladin Mutations in Patients with Familial Pancreatic Cancer
Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1328 - 1330.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Larghi, E. C. Verna, P. G. Lecca, and G. Costamagna
Screening for Pancreatic Cancer in High-Risk Individuals: A Call for Endoscopic Ultrasound
Clin. Cancer Res., March 15, 2009; 15(6): 1907 - 1914.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. R. Ferrone, D. A. Levine, L. H. Tang, P. J. Allen, W. Jarnagin, M. F. Brennan, K. Offit, and M. E. Robson
BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma
J. Clin. Oncol., January 20, 2009; 27(3): 433 - 438.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
K. Brune, S.-M. Hong, A. Li, S. Yachida, T. Abe, M. Griffith, D. Yang, N. Omura, J. Eshleman, M. Canto, et al.
Genetic and Epigenetic Alterations of Familial Pancreatic Cancers
Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3536 - 3542.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
G. Feldmann and A. Maitra
Molecular Genetics of Pancreatic Ductal Adenocarcinomas and Recent Implications for Translational Efforts
J. Mol. Diagn., March 1, 2008; 10(2): 111 - 122.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Wang, C. Szabo, C. Qian, P. G. Amadio, S. N. Thibodeau, J. R. Cerhan, G. M. Petersen, W. Liu, and F. J. Couch
Mutational Analysis of Thirty-two Double-Strand DNA Break Repair Genes in Breast and Pancreatic Cancers
Cancer Res., February 15, 2008; 68(4): 971 - 975.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Wang, S. Chen, K. A. Brune, R. H. Hruban, G. Parmigiani, and A. P. Klein
In Reply
J. Clin. Oncol., November 20, 2007; 25(33): 5337 - 5338.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Abe, N. Fukushima, K. Brune, C. Boehm, N. Sato, H. Matsubayashi, M. Canto, G. M. Petersen, R. H. Hruban, and M. Goggins
Genome-Wide Allelotypes of Familial Pancreatic Adenocarcinomas and Familial and Sporadic Intraductal Papillary Mucinous Neoplasms
Clin. Cancer Res., October 15, 2007; 13(20): 6019 - 6025.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J. B Greer and D. C Whitcomb
Role of BRCA1 and BRCA2 mutations in pancreatic cancer
Gut, May 1, 2007; 56(5): 601 - 605.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Wang, S. Chen, K. A. Brune, R. H. Hruban, G. Parmigiani, and A. P. Klein
PancPRO: Risk Assessment for Individuals With a Family History of Pancreatic Cancer
J. Clin. Oncol., April 10, 2007; 25(11): 1417 - 1422.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Gallmeier, T. Hucl, J. R. Brody, D. A. Dezentje, K. Tahir, J. Kasparkova, V. Brabec, K. E. Bachman, and S. E. Kern
High-Throughput Screening Identifies Novel Agents Eliciting Hypersensitivity in Fanconi Pathway-Deficient Cancer Cells
Cancer Res., March 1, 2007; 67(5): 2169 - 2177.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
F. J. Couch, M. R. Johnson, K. G. Rabe, K. Brune, M. de Andrade, M. Goggins, H. Rothenmund, S. Gallinger, A. Klein, G. M. Petersen, et al.
The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer
Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 342 - 346.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Gallmeier and S. E. Kern
Targeting Fanconi Anemia/BRCA2 Pathway Defects in Cancer: The Significance of Preclinical Pharmacogenomic Models
Clin. Cancer Res., January 1, 2007; 13(1): 4 - 10.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Earl, L. Yan, L. J. Vitone, J. Risk, S. J. Kemp, C. McFaul, J. P. Neoptolemos, W. Greenhalf, for the European Registry of Hereditary Pancreatit, R. Kress, et al.
Evaluation of the 4q32-34 locus in European familial pancreatic cancer.
Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1948 - 1955.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
A. F. Hezel, A. C. Kimmelman, B. Z. Stanger, N. Bardeesy, and R. A. DePinho
Genetics and biology of pancreatic ductal adenocarcinoma.
Genes & Dev., May 15, 2006; 20(10): 1218 - 1249.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
G. M. Petersen, M. de Andrade, M. Goggins, R. H. Hruban, M. Bondy, J. F. Korczak, S. Gallinger, H. T. Lynch, S. Syngal, K. G. Rabe, et al.
Pancreatic cancer genetic epidemiology consortium.
Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 704 - 710.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Jimeno and M. Hidalgo
Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer.
Mol. Cancer Ther., April 1, 2006; 5(4): 787 - 796.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Matsubayashi, M. Canto, N. Sato, A. Klein, T. Abe, K. Yamashita, C. J. Yeo, A. Kalloo, R. Hruban, and M. Goggins
DNA Methylation Alterations in the Pancreatic Juice of Patients with Suspected Pancreatic Disease
Cancer Res., January 15, 2006; 66(2): 1208 - 1217.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. H. Hruban, A. K. Rustgi, T. A. Brentnall, M. A. Tempero, C. V. Wright, and D. A. Tuveson
Pancreatic Cancer in Mice and Man: The Penn Workshop 2004
Cancer Res., January 1, 2006; 66(1): 14 - 17.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
C J van Asperen, R M Brohet, E J Meijers-Heijboer, N Hoogerbrugge, S Verhoef, H F A Vasen, M G E M Ausems, F H Menko, E B Gomez Garcia, J G M Klijn, et al.
Cancer risks in BRCA2 families: estimates for sites other than breast and ovary
J. Med. Genet., September 1, 2005; 42(9): 711 - 719.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Goggins
Molecular Markers of Early Pancreatic Cancer
J. Clin. Oncol., July 10, 2005; 23(20): 4524 - 4531.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
Pancreatic Section
Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas
Gut, June 1, 2005; 54(suppl_5): v1 - v16.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
F. J. Couch, M. R. Johnson, K. Rabe, L. Boardman, R. McWilliams, M. de Andrade, and G. Petersen
Germ Line Fanconi Anemia Complementation Group C Mutations and Pancreatic Cancer
Cancer Res., January 15, 2005; 65(2): 383 - 386.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. E. Garber and K. Offit
Hereditary Cancer Predisposition Syndromes
J. Clin. Oncol., January 10, 2005; 23(2): 276 - 292.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. S. Van der Heijden, J. R. Brody, E. Gallmeier, S. C. Cunningham, D. A. Dezentje, D. Shen, R. H. Hruban, and S. E. Kern
Functional Defects in the Fanconi Anemia Pathway in Pancreatic Cancer Cells
Am. J. Pathol., August 1, 2004; 165(2): 651 - 657.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Beger, M. Ramadani, S. Meyer, G. Leder, M. Kruger, K. Welte, F. Gansauge, and H. G. Beger
Down-Regulation of BRCA1 in Chronic Pancreatitis and Sporadic Pancreatic Adenocarcinoma
Clin. Cancer Res., June 1, 2004; 10(11): 3780 - 3787.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
A. B. Lowenfels and P. Maisonneuve
Epidemiology and Prevention of Pancreatic Cancer
Jpn. J. Clin. Oncol., May 1, 2004; 34(5): 238 - 244.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Koopmann, P. Buckhaults, D. A. Brown, M. L. Zahurak, N. Sato, N. Fukushima, L. J. Sokoll, D. W. Chan, C. J. Yeo, R. H. Hruban, et al.
Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers
Clin. Cancer Res., April 1, 2004; 10(7): 2386 - 2392.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Koopmann, N. S. Fedarko, A. Jain, A. Maitra, C. Iacobuzio-Donahue, A. Rahman, R. H. Hruban, C. J. Yeo, and M. Goggins
Evaluation of Osteopontin as Biomarker for Pancreatic Adenocarcinoma
Cancer Epidemiol. Biomarkers Prev., March 1, 2004; 13(3): 487 - 491.
[Abstract] [Full Text]

Home page
 JCOHome page
A. Liede, B. Y. Karlan, and S. A. Narod
Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature
J. Clin. Oncol., February 15, 2004; 22(4): 735 - 742.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. S. van der Heijden, R. H. Hruban, and S. E. Kern
Reply
Cancer Res., October 15, 2003; 63(20): 6999 - 7001.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
T. A. Dragani
10 Years of Mouse Cancer Modifier Loci: Human Relevance
Cancer Res., June 15, 2003; 63(12): 3011 - 3018.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. S. van der Heijden, C. J. Yeo, R. H. Hruban, and S. E. Kern
Fanconi Anemia Gene Mutations in Young-onset Pancreatic Cancer
Cancer Res., May 15, 2003; 63(10): 2585 - 2588.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. M. Hempen, L. Zhang, R. K. Bansal, C. A. Iacobuzio-Donahue, K. M. Murphy, A. Maitra, B. Vogelstein, R. H. Whitehead, S. D. Markowitz, J. K. V. Willson, et al.
Evidence of Selection for Clones Having Genetic Inactivation of the Activin A Type II Receptor (ACVR2) Gene in Gastrointestinal Cancers
Cancer Res., March 1, 2003; 63(5): 994 - 999.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. M. Domchek, A. Eisen, K. Calzone, J. Stopfer, A. Blackwood, and B. L. Weber
Application of Breast Cancer Risk Prediction Models in Clinical Practice
J. Clin. Oncol., February 15, 2003; 21(4): 593 - 601.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. M. Petersen and R. H. Hruban
Familial Pancreatic Cancer: Where Are We in 2003?
J Natl Cancer Inst, February 5, 2003; 95(3): 180 - 181.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. A. Hahn, B. Greenhalf, I. Ellis, M. Sina-Frey, H. Rieder, B. Korte, B. Gerdes, R. Kress, A. Ziegler, J. A. Raeburn, et al.
BRCA2 Germline Mutations in Familial Pancreatic Carcinoma
J Natl Cancer Inst, February 5, 2003; 95(3): 214 - 221.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.